BIOCYTOGEN PHARMA. H YC1 (I54) — Cash Flow Quality Index
BIOCYTOGEN PHARMA. H YC1 (I54) has a Cash Flow Quality Index of 2.14x as of December 2025. Operating cash flow of €370.25 Million exceeds net income of €173.20 Million, indicating high earnings quality where cash backs reported profits. Explore BIOCYTOGEN PHARMA. H YC1 debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BIOCYTOGEN PHARMA. H YC1 Cash Flow Quality Index (2024–2025)
Historical Cash Flow Quality Index for BIOCYTOGEN PHARMA. H YC1 across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see I54 cash generation efficiency.
Annual Cash Flow Quality Index for BIOCYTOGEN PHARMA. H YC1 (2024–2025)
Year-by-year earnings quality comparison for BIOCYTOGEN PHARMA. H YC1.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.14x | €370.25 Million | €173.20 Million | ▼ -66.1% |
| 2024 | 6.30x | €211.25 Million | €33.54 Million | — |